Literature DB >> 32295903

Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Yosuke Maeda1, Taichiro Takemura2, Takayuki Chikata3,4, Takeo Kuwata3,4, Hiromi Terasawa5, Riito Fujimoto5, Nozomi Kuse3,4, Tomohiro Akahoshi3, Hayato Murakoshi3,4, Giang Van Tran3,6, Yu Zhang3,4, Chau Ha Pham2, Anh Hong Quynh Pham2, Kazuaki Monde5, Tomohiro Sawa5, Shuzo Matsushita3,4, Trung Vu Nguyen6, Kinh Van Nguyen6, Futoshi Hasebe2, Tetsu Yamashiro2,7, Masafumi Takiguchi3,4.   

Abstract

Cell entry by HIV-1 is mediated by its principal receptor, CD4, and a coreceptor, either CCR5 or CXCR4, with viral envelope glycoprotein gp120. Generally, CCR5-using HIV-1 variants, called R5, predominate over most of the course of infection, while CXCR4-using HIV-1 variants (variants that utilize both CCR5 and CXCR4 [R5X4, or dual] or CXCR4 alone [X4]) emerge at late-stage infection in half of HIV-1-infected individuals and are associated with disease progression. Although X4 variants also appear during acute-phase infection in some cases, these variants apparently fall to undetectable levels thereafter. In this study, replication-competent X4 variants were isolated from plasma of drug treatment-naive individuals infected with HIV-1 strain CRF01_AE, which dominantly carries viral RNA (vRNA) of R5 variants. Next-generation sequencing (NGS) confirmed that sequences of X4 variants were indeed present in plasma vRNA from these individuals as a minor population. On the other hand, in one individual with a mixed infection in which X4 variants were dominant, only R5 replication-competent variants were isolated from plasma. These results indicate the existence of replication-competent variants with different coreceptor usage as minor populations.IMPORTANCE The coreceptor switch of HIV-1 from R5 to CXCR4-using variants (R5X4 or X4) has been observed in about half of HIV-1-infected individuals at late-stage infection with loss of CD4 cell count and disease progression. However, the mechanisms that underlie the emergence of CXCR4-using variants at this stage are unclear. In the present study, CXCR4-using X4 variants were isolated from plasma samples of HIV-1-infected individuals that dominantly carried vRNA of R5 variants. The sequences of the X4 variants were detected as a minor population using next-generation sequencing. Taken together, CXCR4-using variants at late-stage infection are likely to emerge when replication-competent CXCR4-using variants are maintained as a minor population during the course of infection. The present study may support the hypothesis that R5-to-X4 switching is mediated by the expansion of preexisting X4 variants in some cases.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CCR5; CXCR4; HIV-1; coreceptor switch; replication competent

Year:  2020        PMID: 32295903      PMCID: PMC7307085          DOI: 10.1128/JVI.00193-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission.

Authors:  Kristen Chalmet; Kenny Dauwe; Lander Foquet; Franky Baatz; Carole Seguin-Devaux; Bea Van Der Gucht; Dirk Vogelaers; Linos Vandekerckhove; Jean Plum; Chris Verhofstede
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses.

Authors:  Win Thida; Takeo Kuwata; Yosuke Maeda; Tetsu Yamashiro; Giang Van Tran; Kinh Van Nguyen; Masafumi Takiguchi; Hiroyuki Gatanaga; Kazuki Tanaka; Shuzo Matsushita
Journal:  Biochem Biophys Res Commun       Date:  2018-11-20       Impact factor: 3.575

3.  Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection.

Authors:  A Jinno; N Shimizu; Y Soda; Y Haraguchi; T Kitamura; H Hoshino
Journal:  Biochem Biophys Res Commun       Date:  1998-02-13       Impact factor: 3.575

4.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

5.  HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection.

Authors:  Benedikt Simon; Katharina Grabmeier-Pfistershammer; Armin Rieger; Mario Sarcletti; Brigitte Schmied; Elisabeth Puchhammer-Stöckl
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

6.  CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression.

Authors:  Stéphanie Raymond; Pierre Delobel; Maud Mavigner; Michelle Cazabat; Stéphanie Encinas; Corinne Souyris; Patrick Bruel; Karine Sandres-Sauné; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

7.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

9.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.

Authors:  Ute V Solloch; Kathrin Lang; Vinzenz Lange; Irina Böhme; Alexander H Schmidt; Jürgen Sauter
Journal:  Hum Immunol       Date:  2017-10-05       Impact factor: 2.850

View more
  4 in total

1.  Evolution of Multiple Domains of the HIV-1 Envelope Glycoprotein during Coreceptor Switch with CCR5 Antagonist Therapy.

Authors:  Yueqi Du; Ellen Wu; Xiang Gao; Jie Zhang; John C Martin; Bruce A Rosa; Makedonka Mitreva; Lee Ratner
Journal:  Microbiol Spectr       Date:  2022-06-21

Review 2.  The role of CCR5 in HIV-associated neurocognitive disorders.

Authors:  Cecile Riviere-Cazaux; Jessica Cornell; Yang Shen; Miou Zhou
Journal:  Heliyon       Date:  2022-07-14

3.  Unique profile of predominant CCR5-tropic in CRF07_BC HIV-1 infections and discovery of an unusual CXCR4-tropic strain.

Authors:  Xiaoyan Hu; Yi Feng; Kang Li; Yueyang Yu; Abdur Rashid; Hui Xing; Yuhua Ruan; Lingling Lu; Min Wei; Yiming Shao
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

4.  Control of HIV-1 Replication by CD8+ T Cells Specific for Two Novel Pol Protective Epitopes in HIV-1 Subtype A/E Infection.

Authors:  Hung The Nguyen; Nozomi Kuse; Yu Zhang; Hayato Murakoshi; Yosuke Maeda; Yoshiko Tamura; Rie Maruyama; Giang Van Tran; Trung Vu Nguyen; Kinh Van Nguyen; Shinichi Oka; Takayuki Chikata; Masafumi Takiguchi
Journal:  J Virol       Date:  2022-09-26       Impact factor: 6.549

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.